H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $15.00 price target on Actuate Therapeutics (NASDAQ: ACTU).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE